AMG National Trust Bank Acquires 45,996 Shares of Merck & Co., Inc. $MRK
AMG National Trust Bank significantly increased its stake in Merck & Co., Inc. by 151.9%, acquiring an additional 45,996 shares, bringing their total holdings to 76,273 shares valued at approximately $6.402 million. This increase occurred amidst recent insider selling activities where executives sold shares worth over $43 million combined. Analysts maintain a "Moderate Buy" rating for Merck, with an average price target of $124.80.
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees "Clear Path" Beyond Keytruda Patent Cliff
Deutsche Bank has upgraded Merck (MRK) to Buy from Hold, with analyst James Shin increasing the price target to $150 from $115. Shin believes the market is undervaluing Merck due to concerns about Keytruda's patent expiration, but sees a "clear path" for the company beyond this cliff and identifies visible growth drivers outside of Keytruda. This upgrade comes despite Merck's earlier 2026 forecast that fell below Wall Street expectations due to the loss of exclusivity for Januvia and other older medicines.
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent Cliff
Deutsche Bank has upgraded Merck (MRK) to Buy from Hold, raising its price target to $150 from $115, citing a "clear path" for the company beyond the upcoming patent expiration of its blockbuster drug, Keytruda. Analyst James Shin believes the market is undervaluing Merck, emphasizing that the company possesses other visible growth drivers and is poised for trough earnings. Despite a recent lower-than-expected 2026 forecast from Merck due to patent expirations for older drugs like Januvia, the analyst maintains a positive outlook.
Live Biotherapeutic Products And Microbiome CDMO Market Size, Top Share to 2033
The global live biotherapeutic products and microbiome CDMO market was valued at USD 55.19 million in 2024 and is projected to reach USD 1,075.98 million by 2033, growing at a CAGR of 39.10%. This growth is driven by increasing awareness of microbiome-based therapies, advancements in microbial engineering and AI-driven manufacturing, and supportive regulatory frameworks. North America currently dominates the market, while Asia-Pacific is expected to be the fastest-growing region.
L’Oréal Played a Key Role in Sanofi CEO Ouster, Successor Pick
L’Oréal SA, the largest shareholder in Sanofi SA, was instrumental in the recent removal of Sanofi CEO Paul Hudson and the selection of his successor. The French cosmetics giant's involvement led to the appointment of Merck KGaA CEO Belén Garijo to take over from Hudson, whose mandate was up for renewal. Hudson had led Sanofi for six and a half years prior to the corporate shakeup.
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
This article compares Merck (MRK) and Bristol Myers Squibb (BMY) as investment options for 2026, analyzing their fundamentals, growth outlooks, risks, and valuations. While Merck boasts strong oncology sales driven by Keytruda and a robust pipeline, it faces headwinds from patent expirations and declining sales of other drugs. Bristol Myers Squibb also has a strong oncology portfolio and is working to mitigate generic competition for legacy drugs through acquisitions and cost savings. Considering valuation, dividend yield, and near-term outlook, Bristol Myers Squibb is presented as the more compelling investment choice.
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
This article compares Merck (MRK) and Bristol Myers Squibb (BMY) as investment opportunities in 2026, analyzing their fundamentals, growth outlooks, risks, and valuations. While Merck boasts strong oncology leadership with Keytruda and a robust pipeline, it faces upcoming patent expirations and declining sales in some segments. Bristol Myers Squibb, despite generic competition for legacy drugs, shows promise with new drug approvals, a strengthened pipeline through strategic acquisitions, and a more favorable valuation and outlook for 2026.
Merck & Co. (MRK) advances on robust Keytruda sales and positive clinical trial results
Merck & Co. (MRK) is experiencing stock growth fueled by strong sales of its blockbuster cancer drug, Keytruda. The company also announced positive results from recent clinical trials, further strengthening its market position and investor confidence. This performance highlights Merck's continued dominance in the pharmaceutical industry and its pipeline potential.
Woodley Farra Manion Portfolio Management Inc. Lowers Holdings in AstraZeneca PLC $AZN
Woodley Farra Manion Portfolio Management Inc. decreased its stake in AstraZeneca PLC by 1.0% in the third quarter of last year, holding 752,814 shares valued at $57.76 million. Despite this slight reduction, other institutional investors have increased their positions in AZN. Analysts have largely maintained a "Buy" or "Overweight" rating on AstraZeneca, with an average target price of $95.75, and the company recently announced a dividend payment.
Merck & Co., Inc. (NYSE:MRK) Now Covered by Analysts at Barclays
Barclays has initiated coverage on Merck & Co., Inc. (NYSE:MRK) with an "overweight" rating and a $140.00 price target, suggesting a 14.91% potential upside. This report follows other analysts who have also recently adjusted their ratings and price targets for Merck, contributing to a consensus "Moderate Buy" rating with a target price of $124.80. The article also details the company's recent stock performance, earnings, and insider trading activity.
Merck & Co., Inc. $MRK Shares Acquired by ICICI Prudential Asset Management Co Ltd
ICICI Prudential Asset Management Co Ltd significantly increased its stake in Merck & Co., Inc. (MRK) by 73.2% in the third quarter, making it their 25th largest holding. This move comes as institutional investors are actively adjusting their positions in MRK, while company insiders have been net sellers. Merck recently reported strong Q3 earnings, beating analyst expectations, and announced a quarterly dividend, signaling solid financial health despite insider selling.
Bristol Myers Squibb Company $BMY Position Trimmed by Jupiter Asset Management Ltd.
Jupiter Asset Management Ltd. has reduced its stake in Bristol Myers Squibb (BMY) by 31.7% in the third quarter, now holding shares worth approximately $41.23 million. This comes as BMY faces mixed sentiment, with the FDA accepting a New Drug Application for an iberdomide combination, potentially creating a new revenue stream, while the company also missed quarterly EPS estimates and received downward revisions from Zacks Research on future earnings. Despite this, BMY increased its quarterly dividend to $0.63, offering a 4.2% yield, and maintains a "Hold" consensus rating from analysts with an average price target of $60.19.
Here Are Friday’s Top Wall Street Analyst Research Calls: Amgen, ETSY, Eldorado Gold, GE Aerospace, Merck, Southern Company, Walmart, Yeti, and More
This article compiles top Wall Street analyst upgrades, downgrades, and initiations for individual stocks on Friday, February 20, 2026. It also provides a brief overview of the market's performance, including futures, treasury bonds, oil and gas, gold, and cryptocurrency, noting that market futures are trading lower despite some positive individual company news. Key analyst calls include upgrades for ETSY and Yeti, and downgrades for Walmart and Eldorado Gold, among others, with new initiations for Amgen, GE Aerospace, and Merck.
NewEdge Wealth LLC Boosts Stake in Merck & Co., Inc. $MRK
NewEdge Wealth LLC increased its stake in Merck & Co., Inc. by 16.4% in the third quarter, bringing their total holdings to 64,291 shares valued at $5.43 million. This comes as Merck reported strong Q1 earnings, beating analyst expectations, and declared a quarterly dividend of $0.85 per share. While institutional investors are boosting their positions, company insiders have sold a significant amount of stock in the last three months.
Rx Rundown: Danaher, Johnson & Johnson, Bayer and more
This article provides an "Rx Rundown" summarizing significant medical marketing news, deal-making, and industry chatter from the previous week. Key highlights include Danaher's acquisition of Masimo for $9.9 billion, Madrigal Pharmaceuticals' $4.4 billion licensing deal, multiple FDA approvals and rejections, notable funding rounds, and industry news such as Bayer's $7.25 billion Roundup settlement and Johnson & Johnson's expansion and paused clinical trials.
29,451 Shares in Merck & Co., Inc. $MRK Bought by CenterBook Partners LP
CenterBook Partners LP recently acquired 29,451 shares of Merck & Co., Inc. (NYSE:MRK) during the third quarter, valued at approximately $2.47 million. Other institutional investors like Charles Schwab Investment Management and DLD Asset Management LP also significantly increased their holdings in Merck, indicating strong institutional interest. Merck reported a recent quarterly dividend of $0.85 per share and exceeded analyst expectations for its last earnings report.
Nicotine Gum Market Analysis Report 2026-2035: A $2.55 Billion Market by 2030 with Pfizer, GlaxoSmithKline, Haleon, Perrigo Co, and Johnson & Johnson Leading
The nicotine gum market is projected to grow from $1.84 billion in 2025 to $2.55 billion by 2030, driven by anti-smoking campaigns, rising health awareness, and increased acceptance of nicotine replacement therapy. Key trends include over-the-counter availability, flavored variants, online distribution, and regulatory support for harm reduction. North America was the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region.
Merck, Mayo Clinic launch AI-driven drug discovery partnership
Merck and Mayo Clinic have formed a partnership to leverage artificial intelligence (AI) and machine learning (ML) with patient data to accelerate drug discovery and development. The collaboration combines Merck's AI research capabilities with Mayo Clinic Platform's infrastructure and extensive clinical datasets, targeting early research decisions in therapeutic areas like gastroenterology, dermatology, and neurology. This move reflects a broader industry trend, with other major pharmaceutical companies also increasing their investments in AI for drug discovery.
Merck to seek 2nd-season RSV nod for Enflonsia in hot pursuit of Sanofi, AZ's Beyfortus
Merck is pushing to expand the label for its RSV antibody, Enflonsia, to include a second RSV season for high-risk infants, aiming to compete more directly with Sanofi and AstraZeneca's Beyfortus. New Smart trial data showed Enflonsia was safe and effective for children entering their second RSV season. This move comes as Beyfortus has seen significant sales, though both products are currently under a safety investigation by the FDA.
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical
The Muscle Invasive Bladder Cancer (MIBC) market is projected for rapid expansion by 2034, driven by an increasing prevalence of the disease, new premium-priced treatment options, and a robust pharmaceutical pipeline. Key market players like CG Oncology, Pfizer, and Janssen R&D are developing advanced therapies, including PD-1 inhibitors and antibody-drug conjugates, that are transforming treatment landscapes, particularly for cisplatin-ineligible patients. Despite challenges like treatment complexity and high costs, significant clinical trial activity and biomarker-driven approaches are expected to fuel future growth.
Where is Merck & Co., Inc. (MRK) Headed According to the Street?
Merck & Co., Inc. (MRK) has been upgraded to a Buy rating by Deutsche Bank with a raised price target due to belief that the market undervalues the company despite the looming Keytruda patent cliff. The firm sees a clear path for the company's growth, excluding Keytruda. Additionally, the FDA approved KEYTRUDA® and KEYTRUDA QLEX™ for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with specific PD-L1+ characteristics, marking them as the first and only PD-1 inhibitors for this indication.
Where is Merck & Co., Inc. (MRK) Headed According to the Street?
Merck & Co., Inc. (NYSE: MRK) has been upgraded to Buy by Deutsche Bank with a raised price target of $150, as the firm believes the market undervalues the company despite the looming Keytruda patent cliff. The analysis projects a clear path for growth beyond Keytruda, with a trough earnings "formation at hand." Additionally, Merck announced FDA approval for KEYTRUDA® and KEYTRUDA QLEX™ for treating specific platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, marking the first and only PD-1 inhibitors approved for this condition.
Merck posts new Enflonsia RSV data in infants (MRK:NYSE)
Merck announced new Phase 3 data for its RSV treatment, Enflonsia (clesrovimab), showing it is safe and effective for infants and children under two years old who are at increased risk during the second season of the virus. This data reinforces the potential of Enflonsia as a therapeutic option for this vulnerable population.
Burling Wealth Partners LLC Sells 9,333 Shares of Merck & Co., Inc. $MRK
Burling Wealth Partners LLC reduced its stake in Merck & Co., Inc. by 23.4% during the third quarter, selling 9,333 shares and retaining 30,486 shares valued at $2.559 million. This sale is part of broader insider selling, with company insiders offloading 320,176 shares worth $38.28 million in the last three months. Despite the insider sales, Merck reported strong quarterly earnings, beating estimates with $2.04 EPS on $16.4 billion revenue, and declared a $0.85 quarterly dividend.
King Luther Capital Management Corp Sells 263,609 Shares of Merck & Co., Inc. $MRK
King Luther Capital Management Corp reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 20.8% in the third quarter, selling 263,609 shares and retaining 1,002,817 shares valued at $84.17 million. Several other hedge funds have also adjusted their positions in Merck, which reported strong quarterly earnings and announced a quarterly dividend of $0.85 per share. Analyst ratings for Merck are generally positive, with a consensus of "Moderate Buy" and an average target price of $123.71, despite recent insider sales by some executives.
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia
BioXcel Therapeutics is hosting a virtual roundtable on February 27, 2026, to discuss acute agitation in Alzheimer's dementia, an area with significant unmet medical need and no FDA-approved treatments. The event will highlight the potential of their investigational product BXCL501, which is currently being evaluated in the TRANQUILITY In-Care Phase 3 trial. Leading medical experts will participate to shed light on this condition that affects approximately 100 million annual episodes.
Merck Discloses Positive Data For Respiratory Syncytial Virus Antibody Treatment, Seeks FDA Nod For Broader Child Use
Merck & Co. has announced positive second RSV season data from its Phase 3 SMART trial for its antibody treatment, Enflonsia, which will be submitted to the FDA for expanded use in children at higher risk for severe RSV. The trial showed consistent safety with previous findings and supported the potential for Enflonsia to protect vulnerable children. Separately, GSK also presented new effectiveness data for its RSV vaccine, AREXVY, demonstrating significant vaccine effectiveness against RSV-related hospitalization.
Hodges Capital Management Inc. Takes Position in Gilead Sciences, Inc. $GILD
Hodges Capital Management Inc. recently acquired 8,635 shares of Gilead Sciences, Inc. (NASDAQ:GILD) valued at approximately $958,000 during the third quarter. This move is part of broader institutional interest, with several other hedge funds also adjusting their positions in the biopharmaceutical company. Meanwhile, company insiders have sold a significant number of shares, while various analysts generally maintain a "Moderate Buy" rating with an average target price of $152.96.
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its critical role in drug development, personalized medicine, and biotech research. Key technologies include X-ray crystallography, NMR, and cryo-EM, with North America currently dominating and Asia-Pacific showing rapid growth due to increased R&D and AI integration. Challenges like high equipment costs and a shortage of skilled personnel persist, but technological advancements and strategic investments are propelling market expansion.
3D Protein Structure Analysis Market Report 2026 Featuring Profiles of Merck, Bruker Corp., Thermo Fisher Scientific, JEOL, Spectris and Other Leading Players
The global 3D protein structure analysis market is projected to grow from $3.4 billion in 2025 to $5.3 billion by 2030, driven by its crucial role in drug development, personalized medicine, and biotech research. Key technologies like X-ray crystallography, NMR, and cryo-EM are central to this growth, with North America currently dominating and Asia-Pacific showing rapid expansion. The market faces challenges such as high equipment costs and a shortage of skilled personnel, but technological advancements and strategic investments are propelling its forward trajectory.
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More
The global market for cell and gene therapy tools and reagents is projected to reach $19.8 billion by 2030, growing at a CAGR of 10.6% from $12 billion in 2025. This growth is driven by increasing clinical and commercial activities in cell and gene therapies (CGTs), significant R&D investments, and regulatory approvals for novel CGTs. The market report provides comprehensive insights into segmentation by product type, application, and end-user, profiling key players such as Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, and Sartorius.
First National Bank of Omaha Makes New Investment in Merck & Co., Inc. $MRK
First National Bank of Omaha has acquired a new stake in Merck & Co., Inc. (NYSE:MRK), purchasing 32,815 shares valued at approximately $2.75 million. This investment comes as other institutional investors have also adjusted their holdings in the pharmaceutical giant. Merck recently reported strong earnings, beating analyst estimates, and announced a quarterly dividend of $0.85 per share.
Sanofi backs Altesa's $75M series B to bankroll rhinovirus study
Sanofi has invested in Altesa BioSciences' oversubscribed $75 million Series B funding round, which will largely fund a Phase 2b study of vapendavir, an antiviral drug targeting rhinovirus infections in patients with chronic obstructive pulmonary disease (COPD). Altesa aims to improve outcomes and reduce healthcare burdens for at-risk patients, building on previous trials showing symptom improvement and reduced illness duration. The company, led by former FDA acting commissioner Brett Giroir, plans to enroll 900 COPD patients in the U.S. and U.K. for the upcoming trial.
7 Most Volatile Stocks Under $5 for Day Trading
The article identifies C4 Therapeutics, Inc. (NASDAQ:CCCC) as one of the most volatile stocks under $5 suitable for day trading. Analysts are bullish on CCCC, projecting a significant upside due to its primary degrader, Cemsidomide, which is progressing through clinical trials. The company has several key clinical and regulatory milestones planned through 2028, including an NDA submission target and multiple phase trials for its oncology and other programs.
Unmasking CytomX - A Pioneer In Masked Therapeutics
CytomX Therapeutics (CTMX) is advancing its PROBODY masking platform with two clinical-stage programs, CX-2051 and CX-801, targeting cancer. CX-2051, an ADC for EpCAM-positive cancers, showed a 28% confirmed response rate in a Phase 1 colorectal cancer study, with further data and combination trials planned. CX-801, an interferon alpha-2b therapeutic, is also in Phase 1 trials for melanoma, demonstrating tolerability, and initial combination data with KEYTRUDA is expected by late 2026.
Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now?
The First Trust Dow 30 Equal Weight ETF (EDOW) is a smart beta ETF that tracks the Dow Jones Industrial Average Equal Weight Index, offering a different approach compared to traditional market-cap-weighted funds. With assets over $295.37 million and an expense ratio of 0.50%, EDOW focuses heavily on the Information Technology sector. The ETF has shown strong performance, gaining 4.67% year-to-date and 14.91% in the past year, making it an option for investors seeking to outperform the large-cap blend market segment.
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Merck announced positive second-season data from its Phase 3 SMART trial for ENFLONSIA™ (clesrovimab), indicating its potential to protect infants and children under two years of age at high risk for severe RSV disease through a second RSV season. The data, presented at RSVVW’26, showed safety consistent with the first season and similar serum concentrations as healthy infants in a previous trial, supporting expanded indication. ENFLONSIA is currently approved in several countries for an infant's first RSV season, and these new findings will be shared with regulatory authorities, including the U.S. FDA, to seek approval for its use in a second RSV season for high-risk children.
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
Merck announced positive second-season results from the Phase 3 SMART trial for ENFLONSIA™ (clesrovimab), indicating its safety and efficacy in infants and children under two years old at increased risk for severe Respiratory Syncytial Virus (RSV) disease. The data, presented at the 9th RSVVW Conference, showed consistent safety and comparable monoclonal antibody serum concentrations to previous trials. These findings support the potential for an expanded indication for ENFLONSIA to protect high-risk children through their second RSV season, building on its existing FDA approval for first-season use.
Health care’s next chapter: Opportunities in an era of transformation
The health care sector is entering a new era of innovation, presenting compelling opportunities for investors despite past challenges. Key subsectors like biotech, life science tools, and managed care are driving this transformation, fueled by scientific advancements and evolving market dynamics. Active management and rigorous research are deemed essential for navigating the sector's complexities and identifying leading companies.
Novartis/Unnatural Team Up On Macrocyclic Peptides
Novartis has partnered with Unnatural Products to collaborate on the development of macrocyclic peptides. This collaboration aims to leverage the expertise of both companies in drug discovery. The article was published on February 18, 2026.
Glaukos Stock Shoots Up After iDose TR Re-administration Approval
Glaukos Corporation (NYSE: GKOS) stock surged over 13% following FDA approval for the re-administration of its iDose TR glaucoma therapy, indicating enhanced patient safety and effectiveness. This regulatory validation has led to increased investor confidence, with Stifel raising Glaukos's price target to $160, and the company forecasting 2026 revenue to exceed expectations due to strategic market positioning and innovative solutions. Recent Q4 revenues also outperformed analyst predictions, underscoring the success of its eyecare products and promising financial health moving forward.
Illumina Stock is Down 80% From Its All-Time Highs: Can It Recover in 2026?
Illumina stock is down 80% from its all-time highs, but recent Q4 2025 earnings show promise with revenue beat and clinical consumables growth. The company completed the SomaLogic acquisition, adding proteomics, which is expected to contribute to revenue growth despite some EPS dilution and margin compression. A TIKR valuation model projects an 11% annualized return to $158 by December 2028, contingent on sustained clinical consumables momentum and successful integration of SomaLogic.
Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery
Merck (NYSE: MRK) has announced a strategic collaboration with Mayo Clinic to integrate AI and advanced analytics into drug discovery. This partnership aims to accelerate the development of personalized therapies by leveraging Mayo Clinic's extensive clinical data to validate AI models. The initial focus will be on therapeutic areas like inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Merck & Company Stock Forecast 2026–2030 | Future Outlook
This article provides a Merck & Company (MRK) stock forecast for 2026-2030, based on third-party price targets and technical analysis. As of February 11, 2026, MRK was trading around $116.29, with analysts' 12-month price targets ranging from $114.53 to $143.37. The stock's performance is influenced by earnings, clinical data, policy developments, and market sentiment, with recent price action linked to the company's Q4 2025 earnings and 2026 outlook.
J&J fleshes out US investment plan, telegraphing $1B cell therapy plant and 500 new jobs in PA
Johnson & Johnson plans to invest over $1 billion in a new cell therapy production plant in Montgomery County, Pennsylvania, creating 500 permanent biomanufacturing jobs and 4,000 construction jobs. This investment is part of J&J's broader $55 billion U.S. expansion strategy aimed at addressing potential pharmaceutical tariffs and boosting domestic production. The new facility will support the growing demand for cell therapies like Carvykti, which already exceeded blockbuster status last year and has previously faced supply constraints.
Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results
Merck & Co. (MRK) has seen its shares advance due to strong sales of its oncology and immunology medications, particularly Keytruda, and positive clinical trial results. Impax US Sustainable Economy Fund highlighted MRK in its Q4 2025 investor letter, noting the company's strong Corporate Resilience and strategic positioning in healthcare access and innovation. Despite its strong performance, Merck is not among the 30 most popular stocks for hedge funds, with 92 hedge funds holding MRK at the end of Q3 2025.
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
Evinova has announced strategic collaborations with Astellas Pharma Inc., AstraZeneca, and Bristol Myers Squibb to accelerate global clinical development using its AI-native platform. These partnerships involve sharing operational data to enhance the platform's recommendations, aiming for faster trials and improved patient outcomes. The AI-driven platform offers solutions like Study Designer, AI Authoring, and AI Digitizer to optimize study design, streamline document creation, and convert clinical data into machine-readable formats, significantly reducing costs and timelines for drug development.
Johnson & Johnson will spend $1 billion on a cell therapy plant on its campus near Ambler
Johnson & Johnson plans to invest over $1 billion to construct a cell therapy manufacturing facility on its Janssen campus near Ambler, Montgomery County, Pennsylvania. This new plant is expected to create 500 jobs and will enhance J&J's capacity to produce cell therapy treatments for various diseases. The investment is supported by $41.5 million in state aid from the Pennsylvania government, highlighting the region's growing hub for life sciences and manufacturing.
Crescent Biopharma doses first patient in ASCEND cancer trial
Crescent Biopharma has dosed the first patient in its global ASCEND Phase 1/2 clinical trial for CR-001, an investigational bispecific antibody targeting advanced solid tumors. The trial will assess the safety, tolerability, and preliminary antitumor activity of CR-001 in up to 290 patients across various solid tumor types. This marks a significant milestone for the company, which expects to report proof-of-concept clinical data in the first quarter of 2027.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. reported its Q4 and full-year 2025 financial and operating results, highlighting a year of significant growth with total revenue up 38% to $1.4 billion and royalty revenue increasing 52% to $868 million. The company expanded its drug delivery portfolio through acquisitions of Hypercon and Surf Bio technologies, broadening its collaboration opportunities. Halozyme also discussed the strong performance of ENHANZE-enabled products like DARZALEX, PHESGO, and VYVGART Hytrulo, along with projections for continued revenue growth and strategic initiatives for long-term value creation into the 2040s.
